Health
Prior Authorization Reform for Autoimmune and Blood Disorders Act
- Introduced
- Committee
- House
- Senate
- President
- Law
- Introduced
- June 8, 2026
- Sponsor
- · D–TX
- Recorded roll calls
- None recorded
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Read FactVote summary
The bill would require group health plans and health insurance issuers offering group or individual coverage to cover drugs or biological products prescribed for autoimmune diseases, hemophilia, or Von Willebrand disease, regardless of how the drug is provided. It would generally limit prior authorization for these drugs to once during any 12-month period, with exceptions for drugs typically used for 12 months or less, certain controlled substances, and drugs requiring a risk evaluation and mitigation strategy. The changes would apply to plan years beginning on or after January 1, 2027, through amendments to ERISA, the Public Health Service Act, and the Internal Revenue Code.
FactVote-generated overview; it is not an official CRS summary.